Erratum: Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors? (Nature Clinical Practice Cardiovascular Medicine (2006) vol. 3: (364-365) doi: 10.1038/ncpcardio0598));Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors? Commentary

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 7, 2006, Pages 364-365

  Tonstad, Serena ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiometabolic risk; Obesity; Rimonabant

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT; TRIACYLGLYCEROL;

BASAL METABOLIC RATE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LOW CALORY DIET; METABOLIC DISORDER; OBESITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 33745548550     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0658     Document Type: Erratum

References (4)

1. Douketis JD et al. (2005) Systematic review of long-term weight loss studies in obese adults: Clinical significance and applicability to clinical practice. Int J Obes (Lond) 29: 1153-1167
2. Curioni CC and Lourenco PM (2005) Long-term weight loss after diet and exercise: A systematic review. Int J Obes (Lond) 29: 1168-1174
3. Padwal R et al. (2006) Long-term pharmacotherapy for obesity and overweight. The Cochrane Database of Systematic Reviews, Issue 2, Art. No CD004094
4. James WP et al. (2000) Effect of sibutramine on weight maintenance after weight loss: A randomised trial. Lancet 356: 2119-2125